Additional file 4: of Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Meihua Wang(University of Electronic Science and Technology of China), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Chen Hu(Central South University), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sunyu Kang(Harvard University), Cong Chen(Fujian University of Traditional Chinese Medicine), Xiaoyun Li(Nanjing University), Thomas Jemielita(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 0
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k